Abstract
Tumor heterogeneity was traditionally considered in the genetic terms, but it has now been broadened into many more facets. These facets represent a challenge in our understanding of cancer etiology but also provide opportunity for us to understand prognosis and therapy response.Citation
Pe’er D, Ogawa S, Elhanani O, Keren L, Oliver TG, Wedge D. Tumor heterogeneity. Cancer Cell. 2021 Aug;39(8):1015–7.Journal
Cancer CellDOI
10.1016/j.ccell.2021.07.009PubMed ID
34375606Additional Links
https://dx.doi.org/10.1016/j.ccell.2021.07.009Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ccell.2021.07.009
Scopus Count
Collections
Related articles
- Bronchioalveolar lung cancer: screening and overdiagnosis.
- Authors: Braillon A
- Issue date: 2014 Nov 1
- Reply to A. Braillon.
- Authors: Johnson DH, Schiller JH, Bunn PA
- Issue date: 2014 Nov 1
- [Research Progress of Immunotherapy and Prognostic Markers in Small Cell Lung Cancer].
- Authors: Wang Q, Peng W, Jiang M, Wu L
- Issue date: 2020 Mar 20
- Breaking the Impasse: Advances in Treatment of Small Cell Lung Cancer.
- Authors: Saltos A, Antonia S
- Issue date: 2020 Jun
- [Advances about treatment of small cell lung cancer].
- Authors: Zhou S, Huang Y, Zhao Z, Wang L
- Issue date: 2011 Oct